Healthcare Industry News: Terumo
News Release - October 10, 2006
Isolagen Adds Key ExecutivePearce to Assume Responsibility for Manufacturing Operations
EXTON, Pa., Oct. 10 (HSMN NewsFeed) -- Isolagen, Inc. (Amex: ILE ) announced today the appointment of Bryant "Rusty" Pearce to Senior Vice President, Operations, which includes responsibility for the company's manufacturing. In his new position, Mr. Pearce will be charged with implementing strategy, solutions and processes to streamline manufacturing, execute the successful commercial ramp up of the company's autologous cell manufacturing, and support all business development efforts. He will report to Nicholas L. Teti, Jr., Isolagen's Chairman and Chief Executive Officer, and be a member of the executive management team.
"I am very pleased to announce the appointment of Rusty Pearce to this key position," stated Mr. Teti. "Rusty is an outstanding talent and will bring a new dimension to the Isolagen team. I am confident that his extensive experience and discipline will bring a strong, short term and strategic presence to enhancing the clinical and commercial viability of our manufacturing process."
Before joining Isolagen, Mr. Pearce spent more than thirty years as an engineering and manufacturing professional who successfully drove product ideas through development, engineering design, manufacturing and regulatory approval. He most recently served as Vice President, Manufacturing and Tech Transfer for Clearant, Inc. Prior, he served in senior manufacturing positions with Terumo Medical Corporation, Fisher Scientific Company and Becton Dickinson.
ABOUT ISOLAGEN, INC.
Isolagen specializes in the development and commercialization of autologous cellular therapies for soft and hard tissue regeneration. The company's product candidates are based on its proprietary Isolagen Process. Autologous cellular therapy is the process whereby a patient's own cells are extracted, allowed to multiply and then injected into the patient. Isolagen's product candidates are designed to be minimally invasive and non-surgical. For additional information, please visit: http://www.isolagen.com.
This press release includes statements that are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 and the provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. While management has based any forward-looking statements contained in the release on its current expectations, the information on which such expectations were based may change. These forward-looking statements rely on a number of assumptions concerning future events and are subject to a number of risks, uncertainties, and other factors, many of which are outside of Isolagen's control, that could cause actual results to materially differ from such statements. Such risks, uncertainties, and other factors include, but are not necessarily limited to, those set forth under the caption "Item 1A. Risk Factors" in Isolagen's most recent Form 10-K filing, as updated in "Item 1A. Risk Factors" in Isolagen's most recent Form 10-Q filing. In addition, Isolagen operates in a highly competitive and rapidly changing environment, and new risks may arise. Accordingly, investors should not place any reliance on forward-looking statements as a prediction of actual results. Isolagen disclaims any intention to, and undertakes no obligation to, update or revise any forward-looking statement. Readers are also urged to carefully review and consider the various disclosures in Isolagen's annual report on Form 10-K, filed with the SEC on March 14, 2006, as well as other public filings with the SEC since such date.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.